Skip to main content
Clinical Trials/NCT03302806
NCT03302806
Completed
N/A

Observational Study to Assess Effect and Safety of High Dose of Biotin (Qizenday®) in Progressive Multiple Sclerosis

Nantes University Hospital1 site in 1 country103 target enrollmentJune 29, 2016

Overview

Phase
N/A
Intervention
Not specified
Conditions
Progressive Multiple Sclerosis
Sponsor
Nantes University Hospital
Enrollment
103
Locations
1
Primary Endpoint
Evolution of post-treatment disability
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

The purpose of this observational study is to collect efficacy and safety data in real life condition within the first year of treatment in patients with progressive multiple receiving a daily dose of biotine of 300 mg.

Registry
clinicaltrials.gov
Start Date
June 29, 2016
End Date
October 24, 2018
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Progressive multiple sclerosis patients with an EDSS score ≤ 7 who have been prescribed high dose of biotin (temporary use administration) at Nantes university hospital (France)

Exclusion Criteria

  • Patient with remittent recurrent multiple sclerosis
  • Pregnant women or women contemplating pregnancy

Outcomes

Primary Outcomes

Evolution of post-treatment disability

Time Frame: 12 months

Change in Expanded Disability Status Scale (EDSS) progression from pretreatment period

Secondary Outcomes

  • CGI-t scale(after 6 months and 12 months)
  • Functional disability : Multiple sclerosis Functional composite(12 months)
  • Ambulation(12 months)
  • adverse effect (adverse drug reaction)(12 months)
  • Quality of life(12 months)

Study Sites (1)

Loading locations...

Similar Trials